Boston Scientific wins UK NICE support for GreenLight laser therapy

Boston Scientific (NYSE:BSX) said Tuesday that the U.K.’s National Institute for Health and Care Excellence now provides guidance supporting the use of its GreenLight XPS laser therapy system used to treat prostatic enlargement in patients with benign prostatic hyperplasia. NICE, which provides evidence-based guidance and standards to the U.K.’s National Health Service, said that adoption of the GreenLight XPS system to treat non high-risk patients with BPH can “significantly reduce costs for the NHS,” Marlborough, Mass.-based Boston Scientific said. “The GreenLight XPS System is a well-established treatment to help men with BPH. It is suitable for almost all men, even those who may not be deemed fit for conventional surgery. The positive guidance from NICE will give more men access to the GreenLight XPS System and may allow surgeons to treat patients on an outpatient basis, with excellent outcomes and with fewer complications,” Dr. Gordon Muir, of London’s King’s College Hospital said in a press release. The Institute said that adoption of the system over current surgical treatment could result in savings of between $3.2 million (£2.3 million) and $4.5 million (£3.2 million) annually for the NHS. “Using technology to improve care and lower health care costs directly benefits patients, hospitals and providers. NICE is internationally recognized for its evidence-based review process and this guidance demonstrates the im...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Urology Boston Scientific Source Type: news